THE EFFECT OF BROMOCRIPTINE ON HUMAN UVEITIS

近年来，越来越多的证据表明， 文献表明垂体激素能够调节 免疫系统 有证据表明，催乳素是一种 免疫刺激激素与血清催乳素降低 实验动物体内的水平 溴隐亭将导致一定程度的免疫抑制。 这一信息已被应用于人类和两个临床 研究已经开始。 这两种都是早期的病人 招聘 其中一项研究是安慰剂和 溴隐亭治疗复发性前葡萄膜炎的终点 每年的复发次数，以确定是否 溴隐亭能够调节这些人的免疫系统。 患者 第二次试验侧重于以下因素的累加效应： 环孢素+溴隐亭治疗 后葡萄膜炎在较低剂量的环孢素，以减少其 并发肾毒性，同时达到 免疫抑制作用。 环孢菌素和催乳素竞争 淋巴细胞上的结合位点。 对人类疾病的进一步研究将有望阐明其他 神经内分泌轴的各个方面，可用于 调节免疫系统以治疗自身免疫性疾病。

In recent years there has been increasing evidence in the literature that pituitary hormones are capable of regulating the immune system. There is evidence to suggest that prolactin is an immunostimulatory hormone and that reduction of serum prolactin levels in experimental animals by hypothesectomy or treatment with bromocriptine will result in a degree of immunosuppression. This information has been applied to humans and two clinical studies have begun. Both of these are in early phase of patient recruitment. One study is a randomized trial between placebo and bromocriptine in recurrent anterior uveitis using the end point of the number of recurrences per year to determine whether bromocriptine is capable of regulating the immune system in these patients. The second trial focuses on the additive effects of cyclosporine plus bromocriptine in attempts to treat patients with posterior uveitis at lower doses of cyclosporine to reduce its concurrent renal toxicity while at the same time achieve an immunosuppressive effect. Cyclosporine and prolactin compete for binding sites on the lymphocyte. Further studies in human disease will hopefully elucidate other aspects of the neuroendocrine axis which can be utilized to regulate the immune system to treat autoimmune diseases.